Impact BioMedical

Impact BioMedical is a holding company that primarily operates through its wholly-owned subsidiary, Global BioLife, Inc. Impact BioMedical drives mission-oriented discovery and development to pursue new products and treatment solutions in the specialty biopharmaceuticals and consumer healthcare sectors. Impact BioMedical is committed to funding the research and development of an intellectual property portfolio. Impact BioMedical currently focuses on research in three main areas: (i) the development of a universal therapeutic platform; (ii) a novel sugar substitute; (iii) multi-purpose spices. Impact Biomedical Inc. (IBIO) is a subsidiary of DSS Inc. Impact BioMedical primarily operates through its subsidiary, Global BioLife, providing funding for the research and development of an intellectual property portfolio. The company currently focuses on research in three main areas: the development of a universal therapeutic platform, a novel sugar substitute, and multi-purpose spices. Impact BioMedical discovers, validates unique scientific and technological innovations, and patents them, which can be developed into new products in human healthcare and wellness through licensing, co-development, joint ventures, and other partnerships with external collaborators. Through its wholly-owned subsidiaries, Global BioLife and Impact BioLife, Impact BioMedical holds a biomedical intellectual property portfolio, including intellectual property assigned by GRDG to Global BioLife.